MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Advanced Breast Cancer Therapies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

898 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
898 works in the cohort · of 4,299,418page 6 of 18

Labels cover 3 of 898 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 898 of 898 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)
Kevin Kalinsky, William E. Barlow, Julie R. Gralow, Funda Meric‐Bernstam, Kathy S. Albain, Daniel F. Hayes +28 more
2022· article· en· Cancer Research· Medicine
machine prediction:candidate · noneconsensus · none
10
citations
affunlabeled
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials
Francisco Cézar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, Jonathan N. Priantti, Giovanna da Conceição Gomes, Sarah Vitória Bristot Carnevalli +6 more
2024· article· en· Journal of Personalized Medicine· Medicine
machine prediction:candidate · noneconsensus · none
10
citations
affunlabeled
Abstract PD15-01: Impact of <i>ESR1</i> mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial
Hope S. Rugo, Eva Ciruelos, Manuel Ruíz‐Borrego, Pamela Drullinsky, Florence Lerebours, Aleix Prat +8 more
2022· article· en· Cancer Research· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affunlabeled
Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study
Sara A. Hurvitz, Vanesa Quiroga, Yeon Hee Park, Aditya Bardia, Vanesa López-Valverde, Jutta Steinseifer +4 more
2022· article· en· Cancer Research· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affno abstractunlabeled
144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study
Amit Bardia, T.M. Fernando, Peter A. Fasching, Y.H. Park, J.M. Giltnane, Cloris Xue +5 more
2022· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
8
citations
affunlabeled
A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.
Richard S. Finn, Véronique Dièras, Karen A. Gelmon, Nadia Harbeck, Stephen E. Jones, María Koehler +8 more
2013· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
8
citations
← previousnext →

How this was built: Screen · Findings · About